Payment overview · 2025
General Payments
$91.97
4 reported records · 3 companies
Healthcare provider profile · identity verified
Clare Brownlee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MISSOULA, MT · NPI 1831282862
Verified facts
What the public records show
CMS Open Payments records show Clare Brownlee, MD received $91.97 in general payments during 2025 across 4 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.65 | 43.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.80 | 33.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.52 | 23.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.97 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 117 |
| Losartan Potassium | Losartan Potassium | 476 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 80 |
| Lisinopril | Lisinopril | 316 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 49 |
| Simvastatin | Simvastatin | 183 | 45 |
| Potassium Chloride | Potassium Chloride | 181 | 41 |
| Omeprazole | Omeprazole | 172 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 34 |
| Gabapentin | Gabapentin | 152 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 26 |
| Furosemide | Furosemide | 124 | 28 |
| Meloxicam | Meloxicam | 112 | 31 |
| Carvedilol | Carvedilol | 109 | 23 |
| Metformin Hcl | Metformin Hcl | 109 | 29 |
| Trazodone Hcl | Trazodone Hcl | 107 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 19 |
| Eliquis | Apixaban | 91 | 13 |
| Spironolactone | Spironolactone | 84 | 23 |
| Ozempic | Semaglutide | 83 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 16 |
| Synthroid | Levothyroxine Sodium | 78 | 21 |
| Alendronate Sodium | Alendronate Sodium | 77 | 24 |
| Sertraline Hcl | Sertraline Hcl | 75 | 16 |
| Celecoxib | Celecoxib | 73 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 12 |
| Montelukast Sodium | Montelukast Sodium | 71 | 23 |
| Jardiance | Empagliflozin | 70 | 17 |
| Bupropion Xl | Bupropion Hcl | 65 | 13 |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Chlorthalidone | Chlorthalidone | 58 | 12 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Allopurinol | Allopurinol | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 14 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 11 |
| Estradiol | Estradiol | 36 | 16 |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Valacyclovir | Valacyclovir Hcl | 35 | 16 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 12 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Cephalexin | Cephalexin | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.97 · 4 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Cologuard Collection Kit, JARDIANCE, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error